NewsBenzingaReported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis Benzinga 2026.09.21 06:32 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 VinFast Says Real Estate Could Cover Its EV Cash Burn Wells Fargo Maintains Overweight on Silgan Hldgs, Lowers Price Target to $52 Piper Sandler Maintains Neutral on First Finl Bankshares, Lowers Price Target to $33 $1000 Invested In Extra Space Storage 20 Years Ago Would Be Worth This Much Today
